News
CYCCP
16.00
-1.84%
-0.30
BRIEF-Cyclacel Pharmaceuticals - Received Nasdaq Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing On Jan 4
Reuters · 01/06 21:21
BRIEF-Cyclacel Pharmaceuticals Reviews 2022 Achievements
Reuters · 01/05 15:52
Cyclacel Pharmaceuticals Reviews 2022 Achievements And Announces Key Business Objectives For 2023
Benzinga · 01/05 14:16
BRIEF-Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results
Reuters · 11/09/2022 21:14
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce thi...
GlobeNewswire · 11/03/2022 13:15
BRIEF-Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial Of Oral Fadraciclib
Reuters · 10/26/2022 13:33
Cyclacel Reports Preliminary Data From Phase 1/2 Clinical Trial Of Oral Fadraciclib In Patients With Solid Tumors And Lymphoma At ENA 2022
Benzinga · 10/26/2022 13:16
BRIEF-Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34Th Eortc-Nci-Aacr Symposium
Reuters · 10/13/2022 13:21
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium October 26
 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology,
Benzinga · 10/13/2022 13:17
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in fall of 2022 to highlight data update...
GlobeNewswire · 08/10/2022 20:05
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce sec...
GlobeNewswire · 08/03/2022 13:15
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities...
Benzinga · 06/30/2022 16:46
BRIEF-Cyclacel Pharmaceuticals Achieves Key Business Objectives In First Half Of 2022 And Continues To Advance Clinical Pipeline
BRIEF-Cyclacel Pharmaceuticals Achieves Key Business Objectives In First Half Of 2022 And Continues To Advance Clinical Pipeline
Reuters · 06/30/2022 13:17
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activ...
GlobeNewswire · 06/30/2022 13:15
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced t...
GlobeNewswire · 06/22/2022 11:04
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Pub...
GlobeNewswire · 05/11/2022 20:05
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce firs...
GlobeNewswire · 05/04/2022 13:15
BRIEF-Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140
reuters.com · 04/19/2022 13:19
Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Cyc140 In Patients With Advanced Solid Tumors And Lymphomas
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - BERKELEY HEIGHTS, N.J., April 19, 2022
Benzinga · 04/19/2022 13:17
Cyclacel Pharmaceuticals Doses First Patient in Phase 1/2 Trial of Potential Treatment for Advanced Solid Tumors
MT Newswires · 04/19/2022 11:56
More
Webull provides a variety of real-time CYCCP stock news. You can receive the latest news about Cyclacel Phar Pr through multiple platforms. This information may help you make smarter investment decisions.
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.